Shanmugam V, Tokcan N, Chafamo D, Sullivan S, Borji M, Martin H
bioRxiv. 2025; .
PMID: 39896575
PMC: 11785141.
DOI: 10.1101/2025.01.24.631210.
Takahashi H, Ito S, Nakanishi Y, Miura K, Nishimaki H, Nakagawa M
Ann Hematol. 2025; .
PMID: 39820429
DOI: 10.1007/s00277-025-06189-1.
Paczkowska J, Tang M, Wright K, Song L, Luu K, Shanmugam V
Nat Commun. 2024; 15(1):10740.
PMID: 39737927
PMC: 11686379.
DOI: 10.1038/s41467-024-54512-7.
Cashen A
Front Oncol. 2024; 14:1392653.
PMID: 39502311
PMC: 11534676.
DOI: 10.3389/fonc.2024.1392653.
Masand N, Perry T, Pugh M, Fennell E, Hennessy A, Wei W
Haematologica. 2024; 110(1):193-199.
PMID: 39219456
PMC: 11694118.
DOI: 10.3324/haematol.2024.285319.
Intra-tumoral and peripheral blood TIGIT and PD-1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma.
Gunawardana J, Law S, Sabdia M, Fennell E, Hennessy A, Leahy C
Am J Hematol. 2024; 99(11):2096-2107.
PMID: 39152767
PMC: 11469944.
DOI: 10.1002/ajh.27459.
HIV infection is associated with compromised tumor microenvironment adaptive immune reactivity in Hodgkin lymphoma.
Chantziou A, Brenna C, Ioannidou K, Chen O, Korkolopoulou P, Antoniadou A
Blood Adv. 2024; 8(24):6215-6231.
PMID: 39116294
PMC: 11697195.
DOI: 10.1182/bloodadvances.2023012116.
Immune checkpoint inhibitors targeting PD-1/PD-L1 in the treatment of human lymphomas.
Ribatti D, Cazzato G, Tamma R, Annese T, Ingravallo G, Specchia G
Front Oncol. 2024; 14:1420920.
PMID: 39091917
PMC: 11291367.
DOI: 10.3389/fonc.2024.1420920.
Mechanisms of lymphoma-stromal interactions focusing on tumor-associated macrophages, fibroblastic reticular cells, and follicular dendritic cells.
Ohe R
J Clin Exp Hematop. 2024; 64(3):166-176.
PMID: 39085126
PMC: 11528246.
DOI: 10.3960/jslrt.24034.
Multiplexed Spatial Profiling of Hodgkin Reed-Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma.
Pourmaleki M, Jones C, Mellinghoff S, Greenstein B, Kumar P, Foronda M
Clin Cancer Res. 2024; 30(17):3881-3893.
PMID: 38949890
PMC: 11369618.
DOI: 10.1158/1078-0432.CCR-24-0942.
Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.
Zanelli M, Fragliasso V, Parente P, Bisagni A, Sanguedolce F, Zizzo M
Int J Mol Sci. 2024; 25(12).
PMID: 38928153
PMC: 11203507.
DOI: 10.3390/ijms25126447.
Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice.
Savelli C, Bisio M, Legato L, Fasano F, Santambrogio E, Nicolosi M
Cancers (Basel). 2024; 16(10).
PMID: 38791909
PMC: 11120540.
DOI: 10.3390/cancers16101830.
Immune checkpoint inhibitors in advanced and relapsed/refractory Hodgkin lymphoma: current applications and future prospects.
Milrod C, Pelcovits A, Ollila T
Front Oncol. 2024; 14:1397053.
PMID: 38699638
PMC: 11063339.
DOI: 10.3389/fonc.2024.1397053.
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.
Wu D, Li Y, Xu P, Fang Q, Cao F, Lin H
Nat Commun. 2024; 15(1):2177.
PMID: 38467604
PMC: 10928200.
DOI: 10.1038/s41467-024-46444-z.
Macrophages and angiogenesis in human lymphomas.
Ribatti D, Tamma R, Annese T, Ingravallo G, Specchia G
Clin Exp Med. 2024; 24(1):26.
PMID: 38285283
PMC: 10824884.
DOI: 10.1007/s10238-023-01291-y.
Distinct mesenchymal cell states mediate prostate cancer progression.
Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli G, Pannellini T
Nat Commun. 2024; 15(1):363.
PMID: 38191471
PMC: 10774315.
DOI: 10.1038/s41467-023-44210-1.
Checkpoint Immunotherapy in Pediatric Oncology: Will We Say Checkmate Soon?.
Ciurej A, Lewis E, Gupte A, Al-Antary E
Vaccines (Basel). 2023; 11(12).
PMID: 38140246
PMC: 10748105.
DOI: 10.3390/vaccines11121843.
Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas.
Katsuya H, Suzumiya J, Kimura S
Cancers (Basel). 2023; 15(22).
PMID: 38001659
PMC: 10670854.
DOI: 10.3390/cancers15225399.
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
Zhou Y, Borcsok J, Adib E, Kamran S, Neil A, Stawiski K
Sci Adv. 2023; 9(47):eadg2263.
PMID: 37992168
PMC: 10664985.
DOI: 10.1126/sciadv.adg2263.
PD-L1 expression in recurrent or metastatic head and neck squamous cell carcinoma in China (EXCEED study): a multicentre retrospective study.
Lu H, Kuang D, Zhou P, Zeng J, Xia Q, Wang J
J Clin Pathol. 2023; 78(2):88-95.
PMID: 37968103
PMC: 11874279.
DOI: 10.1136/jcp-2023-209059.